MedTrace Logo

A Physiological Study on Downregulation of EGF-receptors in the Skin by Topical Exposition With EGF

NCT01566578 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2012-08-03

No results posted yet for this study

Summary

Investigation of EGF-Receptor Downregulation by topical EGF (dermal cream) exposition.

Conditions

Interventions

DRUG

Human recombinant epidermal growth factor

topical

OTHER

Placebo cream

Dermal cream without EGF

Sponsors & Collaborators

  • University of Zurich

    collaborator OTHER

  • Ennar Pharmaceuticals AF

    lead INDUSTRY

Principal Investigators

  • Thomas Kündig, MD · University Hospital Zurich, Dermatology Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01566578 on ClinicalTrials.gov